Abiopharma

🔍 Thompson Rahsaan (Executive)

Company: ZEVRA THERAPEUTICS, INC. (ZVRA)

Report Date: 2026-06-21

Detailed Transactions and Holdings:

• Acquired 66,667 shares of Common Stock (Direct)
  Date: 2026-06-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 114,792.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 34,557 shares of Common Stock at $12.6835 per share (Direct)
  Date: 2026-06-22 | Code: S | equity_swap_involved: 0 | shares_owned_after: 80,235.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 66,667 shares of Restricted Stock Unit (Derivative)
  Date: 2026-06-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 66,667.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
• F2: Adoption date of referenced 10b5-1(c) plan is: 01-08-2026.
• F3: This transaction was executed in multiple trades at prices ranging from $12.53 to $13.19. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
• F4: The first and second tranches of the restricted stock units vested and settled on June 21, 2025 and June 21, 2026, respectively, and the remaining tranche of the restricted stock units will vest and settle on the next anniversary thereafter, subject to the Reporting person's continued service through such vesting date.